Favorable Outcome After Physiologic Dose of Sodium-<scp>d,l</scp>-3-Hydroxybutyrate in Severe MADD

Willemijn J. van Rijt, M. Rebecca Heiner‐Fokkema, Gideon J. du Marchie Sarvaas, Hans R. Waterham, Robert G. T. Blokpoel, Francjan J. van Spronsen, Terry G. J. Derks

PEDIATRICS · 2014 · 19 citations · 12 references

DOIFull text

Open access

Concepts

Abstract

Multiple acyl coenzyme A dehydrogenase deficiency (MADD) is a severe inborn error of metabolism. Experiences with sodium-D,L-3-hydroxybutyrate (3-HB) treatment are limited although positive; however, the general view on outcome of severely affected patients with MADD is relatively pessimistic. Here we present an infant with MADD in whom the previously reported dose of 3-HB did not prevent the acute, severe, metabolic decompensation or progressive cardiomyopathy in the subsequent months. Only after a physiologic dose of 2600 mg/kg of 3-HB per day were ketone bodies detected in blood associated with improvement of the clinical course, N-terminal prohormone of brain natriuretic peptide and echocardiographic parameters. Long-term studies are warranted on 3-HB treatment in patients with MADD.

References

12